Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Spinal Cord Stimulation to Treat Post-operative Atrial Fibrillation (SCS-PAF)

5 avril 2016 mis à jour par: Medtronic BRC
Patients will be randomized to control and spinal cord stimulation arm (SCS) to investigate the effect of SCS on the occurrence of post-operative atrial fibrillation in the five days after surgery.

Aperçu de l'étude

Description détaillée

Pre market single center clinical research feasibility study. Non blinded randomized controlled study. 52 patients undergoing CABG procedure will be enrolled and randomized into two different group (26 person each): the Spinal Cord Stimulation (SCS) and the control group. The first group will be implanted before the CABG procedure with a temporary SCS lead (5 days) while the second one will not. The lead will be connected to an external stimulator.

The day of the CABG surgery, before the scheduled procedure, the patients in the treatment group will be implanted with the SCS lead. CABG procedure follows the SCS lead implantation. SCS will be switched off before surgery.

After the CABG procedure, all patients will be hospitalized for minimally five days at the end of which they will be discharged. The Primary Endpoint data will be collected from the day of CABG procedure (Day-0) until Day-5. SCS lead will be removed on Day-5.

1-week follow up visit will be performed one week after discharge. End-points will be evaluated at various time before, during and after surgery. In both groups arrhythmic episodes for primary and secondary endpoints will be recorded via a Holter monitor (recording 5 days continuously).

Type d'étude

Interventionnel

Inscription (Réel)

4

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Enschede, Pays-Bas, 7511 JX
        • Medisch Spectrum Twente (MST)

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Patients which will be subjected to an OFF-pump CABG procedure
  2. More than 18 years of age
  3. Subject is able and willing to give informed consent.

Exclusion Criteria:

  1. Patients with known history of atrial arrhythmias.
  2. Patients who are not treated with β-blockers unless heart rate is too low for β-blockers assumption.
  3. Participation in another clinical trial which may affect the outcome within 3 months prior to day of procedure.
  4. Other surgical interventions (e.g. valve replacement) programmed in the same surgical session
  5. Resting pulse rate ≤45 beats / min as assessed before daily doses of β-blockage is administered.
  6. Hypotension (RR systolic <100 or RR diastolic <50).
  7. Conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block or a complete bundle branch block.
  8. Subject is diagnosed with epilepsy or history of seizures.
  9. Coagulation abnormalities as determined by anticoagulation guidelines for neuroaxial procedures 2011.
  10. Patients not stabilized on an anti-arrhythmic drug regimen for the last 30 days.
  11. Patients with long QT syndrome.
  12. Patients with Brugada syndrome.
  13. Patients affected by Polyneuropathy (e.g. due to diabetes).
  14. Patients affected by pericarditis
  15. Patients who underwent procedures in the past, which are expected to have changed the innervation of the heart for example:

    • Ablation procedure
    • Cardiac surgery
  16. Pregnant patients or nursing (subjects who are of child bearing potential and are not on a reliable form of birth control will undergo a pregnancy test)
  17. Patients already implanted with cardiac devices
  18. Patients with existing implanted neurostimulators

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: Conventional treatment
Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
Expérimental: Spinal Cord Stimulation System
This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.
To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
Autres noms:
  • (Medtronic External Neurostimulator Model 37022; Medtronic 1x8 Standard LZ Lead Model 3877; Medtronic MultiLead Trialing Cable MLTC Model 355531)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Atrial fibrillation
Délai: 5 days after CABG
AT/AF will be defined as an episode with an atrial rate >175 bpm lasting ≥ 20 seconds.
5 days after CABG

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Medication
Délai: 5 days after CABG
Description of integral medication related to AT/AF occurrence and pain in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery.
5 days after CABG
Cardioversion
Délai: 5 days after CABG
Description of number of cardioversion needed in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery.
5 days after CABG
Hospitalizations Days
Délai: 1 week after discharge
Description of hospitalizations longer than 5 days as required by the protocol and clinical practice in the treatment (SCS) and control group.
1 week after discharge
BP
Délai: 5 days after CABG
Description of 1) intra arterial blood pressure as averaged over the first 24 hours after surgery and 2) arterial blood pressure as determined using a blood pressure cuff at a specific time on Day-2, Day-3, Day-4 and Day-5 after surgery in the treatment (SCS) and control group.
5 days after CABG
Description of the total number of AT/AF episodes in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery.
Délai: 5 days after CABG
AT/AF episodes
5 days after CABG
Description of burden of AT/AF episodes in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery.
Délai: 5 days after CABG
AT/AF burden
5 days after CABG
Premature atrial beats
Délai: 5 days after CABG
Description of the amount of premature atrial beats in the treatment (SCS) and control group from the end of the procedure till Day-5 after surgery.
5 days after CABG
VT/VF episodes
Délai: 5 days after CABG
Description of the total number of VT/VF episodes in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery.
5 days after CABG
Burden VT/VF episodes
Délai: 5 days after CABG
Description of the burden of VT/VF episodes in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery.
5 days after CABG
HRV
Délai: 5 days after CABG
Improvement LF/HF ratio of Heart Rate Variability (HRV) by SCS. SCS On and Off will be compared in each patients in the treatment (SCS) group before surgery and 5 days after surgery.
5 days after CABG
Pain on the VAS scale
Délai: 5 days after CABG
Description of pain-score due to CABG surgery measured with a VAS score three times a from Day-1 till Day-5 after surgery in the treatment (SCS) and control group.
5 days after CABG
Bladder function
Délai: 5 days after CABG
The extra time the bladder catheter will be kept in the patients after the first 2 days after surgery will be described in the treatment (SCS) and control group in order to assess bladder function.
5 days after CABG
HR
Délai: 5 days after CABG
Description of 1) heart rate as averaged over the first 24 hours after surgery and 2) heart rate as determined using a blood pressure cuff at a specific time on Day-2, Day-3, Day-4 and Day-5 after surgery in the treatment (SCS) and control group.
5 days after CABG

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Jan Diephuis, PhD, Medisch Spectrum Twente

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 février 2015

Achèvement primaire (Réel)

1 février 2016

Achèvement de l'étude (Réel)

1 février 2016

Dates d'inscription aux études

Première soumission

11 mai 2015

Première soumission répondant aux critères de contrôle qualité

19 août 2015

Première publication (Estimation)

20 août 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

6 avril 2016

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 avril 2016

Dernière vérification

1 avril 2016

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner